Abstract
Introduction: The renin-angiotensin system may mediate tumor growth in pancreatic cancer. Drugs inhibiting this system may therefore be associated with survival in patients with pancreatic cancer. We examined the association between prediagnostic use of angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) and survival in pancreatic cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
